Center for Biosimilars2h
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...
centerforbiosimilars1d
Lana Pine
The Banking of Biosimilars: Insights From a Leading Health Economist ...
centerforbiosimilars1d
St John Skilton, PhD
The Banking of Biosimilars: Insights From a Leading Health Economist ...
centerforbiosimilars2d
Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS
Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential ...
centerforbiosimilars2d
Kennedy Ferruggia
The Banking of Biosimilars: Insights From a Leading Health Economist ...
Center for Biosimilars3d
BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio
Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...
centerforbiosimilars3d
Travis Brewer
The Banking of Biosimilars: Insights From a Leading Health Economist ...
centerforbiosimilars3d
Sabina Alikhanov Palmieri, PharmD
The Banking of Biosimilars: Insights From a Leading Health Economist ...
centerforbiosimilars3d
Adrian Goh, MEc
The Banking of Biosimilars: Insights From a Leading Health Economist ...
centerforbiosimilars3d
Denise Myshko
The Banking of Biosimilars: Insights From a Leading Health Economist ...
centerforbiosimilars3d
Paul Cornes, BM, BCH, MA, MRCP, FRCR
The Banking of Biosimilars: Insights From a Leading Health Economist ...